Sermorelin Peptide Therapy Denver | R2 Medical Clinic

Sermorelin

What Is Sermorelin?

Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It consists of the biologically active first 29 amino acids of endogenous human GHRH and is also known as GHRH(1-29)-NH₂.

Sermorelin stimulates the pituitary gland to release the body’s own growth hormone (GH). Increased GH secretion may then increase production of insulin-like growth factor-1 (IGF-1), which is involved in growth, metabolism, body composition, tissue repair, and other physiologic processes.

Sermorelin was previously marketed in the United States under the brand name Geref®. Geref was approved by the FDA in 1997 but was later discontinued. The FDA determined that Geref was not withdrawn for reasons of safety or effectiveness.

Mechanism of Action

Sermorelin acts by binding to GHRH receptors on pituitary somatotroph cells. This stimulates endogenous, pulsatile growth hormone secretion.

Activation of the GHRH receptor may result in:

Increased endogenous growth hormone release

Increased IGF-1 production

Support of normal growth hormone signaling

Stimulation of pituitary growth hormone reserve

Preservation of hypothalamic-pituitary feedback regulation

Unlike recombinant human growth hormone, sermorelin does not replace GH directly. Instead, it stimulates the pituitary gland to release GH through a more physiologic pathway.

Physiological Effects

The GH/IGF-1 axis governs two primary biological functions: Somatic Growth and Metabolism.

Growth (Somatic & Linear)

Bone Growth: GH and IGF-1 promote the division and differentiation of cartilage cells (chondrocytes) in the growth plates of bones, driving linear growth. [1, 2]

Muscle Growth: IGF-1 stimulates the proliferation and maturation of muscle fibers, increasing overall protein synthesis and lean body mass. [1, 2]

Metabolism

Protein Anabolism: GH accelerates amino acid uptake into cells and enhances protein synthesis while preventing protein breakdown.

Lipid Mobilization (Lipolysis): GH triggers the breakdown of triglycerides in adipose tissue, releasing free fatty acids for energy.

Carbohydrate Regulation: To conserve glucose for the brain, GH promotes a temporary state of insulin resistance, decreasing glucose uptake in peripheral tissues like muscle. [1, 2, 3, 4, 5]

Potential Benefits

Potential benefits of sermorelin are related to increased endogenous GH and IGF-1 signaling.

Possible benefits may include:

Increased growth hormone secretion

Support of growth in children with certain forms of growth hormone deficiency

Potential improvement in body composition

Support of lean body mass

Possible improvement in recovery and tissue repair signaling

Possible improvement in sleep quality and vitality in some patients

Diagnostic use in evaluating pituitary GH reserve

It is important to note that many wellness-related uses of sermorelin are off-label and are not FDA-approved. Sermorelin is not FDA-approved for anti-aging, bodybuilding, weight loss, athletic performance, or longevity therapy.

Risks & Side Effects

Sermorelin may cause side effects, especially when used without appropriate medical supervision.

Potential risks and side effects include:

Injection-site pain, redness, swelling, or irritation

Headache

Flushing

Dizziness

Nausea

Sleepiness

Changes in taste

Fluid retention

Joint pain

Muscle pain

Numbness or tingling

Carpal tunnel–type symptoms

Elevated IGF-1

Increased blood glucose or worsening insulin resistance

Hypersensitivity or allergic reaction

Because sermorelin stimulates GH and IGF-1 signaling, caution is appropriate in patients with diabetes, prediabetes, elevated IGF-1, unexplained edema, or a history of malignancy.

Contraindications

Sermorelin should generally be avoided or used only with caution in individuals with:

Active malignancy

History of cancer without specialist clearance

Pregnancy or breastfeeding

Known hypersensitivity to sermorelin or formulation components

Uncontrolled diabetes

Severe insulin resistance

Unexplained elevated IGF-1

Active pituitary tumor or significant hypothalamic-pituitary disease

Severe edema or active carpal tunnel syndrome

Patients considering sermorelin should undergo medical evaluation and monitoring, including assessment of symptoms, medical history, medications, glucose metabolism, and IGF-1 levels when clinically appropriate.

FDA Approval Status

Sermorelin was previously FDA-approved under the brand name Geref®. The FDA orphan drug database lists sermorelin acetate / Geref with a marketing approval date of September 26, 1997.

Geref was later discontinued in the United States. In 2013, the FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness.

Current important points:

Sermorelin is not currently available as an FDA-approved commercial drug product in the United States.

Compounded sermorelin may be prescribed in some settings, but compounded medications are not FDA-approved.

Sermorelin is not FDA-approved for anti-aging, weight loss, bodybuilding, athletic performance, longevity, or hormone optimization.

Human & Animal Studies

Human Studies

Sermorelin and related GHRH(1-29) analogs have been studied in both children and adults.

Clinical studies have evaluated sermorelin/GHRH therapy for:

Growth hormone deficiency in children

Idiopathic short stature or impaired growth velocity

Diagnostic evaluation of GH reserve

Age-related decline in GH secretion

Effects on the somatotropic axis in older adults

A review article describes sermorelin as a 29-amino-acid analog of human GHRH and the shortest synthetic peptide retaining full biologic activity of GHRH.

In children with growth hormone deficiency, once-daily subcutaneous GHRH therapy was shown to accelerate growth during the first year of therapy.

In older adults, nightly administration of a GHRH analog for four months activated the somatotropic axis, increasing GH and IGF-1 activity.

Animal & Preclinical Studies

Preclinical research on GHRH analogs has helped establish their biologic activity and receptor-mediated effects.

Animal and laboratory studies have shown that GHRH analogs can:

Stimulate pituitary GH release

Increase downstream IGF-1 signaling

Demonstrate receptor-specific activity at the GHRH receptor

Support growth-related pathways

Help characterize GH secretion physiology

Animal and preclinical data support the biologic plausibility of sermorelin, but they do not establish safety or effectiveness for common off-label wellness uses in humans.

Published Studies

Sermorelin: A Review of Its Use in the Diagnosis and Treatment of Children With Idiopathic Growth Hormone Deficiencyhttps://pubmed.ncbi.nlm.nih.gov/18031173/

Once Daily Subcutaneous Growth Hormone-Releasing Hormone Therapy Accelerates Growth in Growth Hormone-Deficient Children During the First Year of Therapyhttps://pubmed.ncbi.nlm.nih.gov/8772599/

Treatment With GHRH(1-29)-NH₂ in Children With Idiopathic Short Stature Induces sustained increase in growth velocityhttps://pubmed.ncbi.nlm.nih.gov/7955460/

Intranasal administration of growth hormone-releasing hormone (1-29)-NH2 in children with growth hormone deficiency: effects of growth hormone secretion and growthhttps://pubmed.ncbi.nlm.nih.gov/8329828/

Treatment of Radiation-Induced Growth Hormone Deficiency With Growth Hormone-Releasing Hormonehttps://pubmed.ncbi.nlm.nih.gov/9231053/

Effects of Once-Nightly Growth Hormone-Releasing Hormone Administration in Age-Advanced Men and Womenhttps://pubmed.ncbi.nlm.nih.gov/9141536/

Effects of GHRH(1-29)-NH₂ Administration on the Immune System of Aging Men and Womenhttps://pubmed.ncbi.nlm.nih.gov/9360512/

Responses to Analogues of Growth Hormone-Releasing Hormone in Normal Subjectshttps://pubmed.ncbi.nlm.nih.gov/6236914/

Synthetic Analogues of Growth Hormone-Releasing Hormone, GHRH(1-29)-NH₂ and D-Ala² GHRH(1-29)-NH₂, in Normal Menhttps://pubmed.ncbi.nlm.nih.gov/2866496/

Regulatory / FDA Sources

FDA Federal Register: Determination That Geref Was Not Withdrawn for Reasons of Safety or Effectivenesshttps://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams

FDA Orphan Drug Designations and Approvals: Sermorelin Acetate / Gerefhttps://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687

Review Articles & Scientific Background

Sermorelin: A Better Approach to Management of Adult-Onset Growth Hormone Insufficiency?https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/

Beyond the Androgen Receptor: The Role of Growth Hormone Secretagogues in Men’s Healthhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7108996/

Growth Hormone and Aging — Endotexthttps://www.ncbi.nlm.nih.gov/books/NBK279163/

The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice.

This content was generated with the assistance of artificial intelligence (AI) and reviewed for general accuracy; however, it may contain errors or omissions and should not replace professional medical judgment. Individuals should consult a qualified healthcare provider before beginning or changing any medical treatment.

R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law.

# MK-677 (Ibutamoren)